WCM Investment Management LLC Makes New Investment in Biohaven Ltd. (NYSE:BHVN)

WCM Investment Management LLC acquired a new stake in Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 106,665 shares of the company’s stock, valued at approximately $3,816,000. WCM Investment Management LLC owned approximately 0.11% of Biohaven as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BHVN. nVerses Capital LLC acquired a new position in Biohaven in the 3rd quarter valued at about $50,000. Spire Wealth Management acquired a new position in shares of Biohaven in the fourth quarter valued at approximately $56,000. Values First Advisors Inc. purchased a new position in shares of Biohaven during the third quarter valued at approximately $78,000. US Bancorp DE boosted its position in Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after acquiring an additional 790 shares during the last quarter. Finally, KBC Group NV grew its stake in Biohaven by 24.5% in the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after acquiring an additional 443 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Transactions at Biohaven

In other news, Director John W. Childs purchased 29,000 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the purchase, the director now directly owns 2,368,741 shares of the company’s stock, valued at approximately $85,132,551.54. This represents a 1.24 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 16.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BHVN shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. HC Wainwright restated a “buy” rating and issued a $59.00 price target on shares of Biohaven in a report on Tuesday, December 17th. Finally, TD Cowen increased their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $63.00.

Biohaven Stock Down 1.2 %

BHVN opened at $38.40 on Monday. Biohaven Ltd. has a 52-week low of $26.80 and a 52-week high of $62.21. The company has a 50 day moving average of $38.90 and a two-hundred day moving average of $42.64. The company has a market cap of $3.88 billion, a P/E ratio of -4.11 and a beta of 1.28.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Research analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.